
Medpace Holdings (MEDP) Stock Forecast & Price Target
Medpace Holdings (MEDP) Analyst Ratings
Bulls say
Medpace Holdings anticipates a significant increase in passthrough revenues, projecting a rise of 200-300 basis points in the second half of the year compared to elevated levels observed in the second quarter. Additionally, the company reported strong demand indicators with higher RFP (Request for Proposal) volume in the first quarter, suggesting increased market activity. Furthermore, Medpace expects its book-to-bill ratio to recover above 1.15x in the third quarter, indicating robust growth potential and demand for its clinical trial services.
Bears say
Medpace Holdings has experienced higher-than-normal backlog cancellations, which have only recently begun to decline toward the lower end of its expected range, indicating potential instability in client demand. The company has expressed uncertainty regarding the growth of its Direct Service revenue, which it deems too early to quantify, suggesting challenges in revenue forecasting. Additionally, despite upward revisions in adjusted EBITDA estimates for 2025 and 2026, the continued hiring in direct service costs and anticipated declines in passthrough revenues raise concerns about profitability and operational efficiency moving forward.
This aggregate rating is based on analysts' research of Medpace Holdings and is not a guaranteed prediction by Public.com or investment advice.
Medpace Holdings (MEDP) Analyst Forecast & Price Prediction
Start investing in Medpace Holdings (MEDP)
Order type
Buy in
Order amount
Est. shares
0 shares